

Assessing Medical Decision-Making Competence in Transgender Youth

Lieke J.J.J. Vrouwenraets, MSc,^{a,b,c} Annelou L.C. de Vries, MD, PhD,^b Martine C. de Vries, MD, PhD,^c
Anna I.R. van der Miesen, MD, PhD,^b Irma M. Hein, MD, PhD^d

abstract

BACKGROUND: According to international transgender care guidelines, an important prerequisite for puberty suppression (PS) is transgender adolescents' competence to give informed consent (IC). In society, there is doubt whether transgender adolescents are capable of this, which in some countries has even led to limited access to this intervention. Therefore, this study examined transgender adolescents' medical decision-making competence (MDC) to give IC for starting PS in a structured, replicable way. Additionally, potential associated variables on MDC, such as age, intelligence, sex, psychological functioning, were investigated.

METHODS: A cross-sectional semistructured interview study with 74 transgender adolescents (aged 10–18 years; 16 birth-assigned boys, 58 birth-assigned girls) within two Dutch specialized gender-identity clinics was performed. To assess MDC, judgements based on the reference standard (clinical assessment) and the MacArthur Competence Assessment Tool for Treatment (MacCAT-T), a validated semistructured interview, were used.

RESULTS: Of the transgender adolescents, 93.2% (reference standard judgements; 69 of 74) and 89.2% (MacCAT-T judgements; 66 of 74) were assessed competent to consent. Intermethod agreement was 87.8% (65 of 74). Interrater agreements of the reference standard and MacCAT-T-based judgements were 89.2% (198 of 222) and 86.5% (192 of 222), respectively. IQ and sex were both significantly related to MacCAT-T total score, whereas age, level of emotional and behavioral challenges, and diagnostic trajectories duration were not.

CONCLUSIONS: By using the MacCAT-T and clinicians' assessments, 93.2% and 89.2%, respectively, of the transgender adolescents in this study were assessed competent to consent for starting PS.

Full article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2020-049643

^aDepartment of Child and Adolescent Psychiatry, Leiden University Medical Center Curium, Leiden University Medical Center, Oegstgeest, the Netherlands; ^bDepartment of Child and Adolescent Psychiatry, Amsterdam University Medical Center, Location VUmc, VU University, Amsterdam, the Netherlands; ^cDepartment of Medical Ethics and Health Law, Leiden University Medical Center, Leiden, the Netherlands; and ^dDepartment of Child and Adolescent Psychiatry, Amsterdam University Medical Center and University of Amsterdam, Amsterdam, the Netherlands

Dr A. de Vries and Dr I. Hein conceptualized and designed the study, conducted the initial analyses, and critically reviewed and revised the manuscript; Dr M. de Vries conceptualized and designed the study and critically reviewed and revised the manuscript; Dr A. van der Miesen conducted the initial analyses and critically reviewed and revised the manuscript; Dr L. Vrouwenraets collected data, conducted the initial analyses, and drafted the initial manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

DOI: <https://doi.org/10.1542/peds.2020-049643>

Accepted for publication Jul 15, 2021

WHAT'S KNOWN ON THIS SUBJECT: According to international transgender care guidelines, an important prerequisite for puberty suppression is transgender adolescents' competence to give informed consent (IC). However, some doubt adolescents' ability to provide valid IC because of their age and potential consequences of this decision.

WHAT THIS STUDY ADDS: This study presents empirical outcomes of assessment of transgender adolescents' medical decision-making competence (MDC) to give IC for starting puberty suppression. In addition, potential associated variables on MDC, such as age, intelligence, sex, and psychological functioning, are presented.

To cite: Vrouwenraets LJ.J.J, de Vries AL.C, de Vries MC, et al. Assessing Medical Decision-Making Competence in Transgender Youth. *Pediatrics*. 2021;148(6):e2020049643

In December 2020, the High Court of Justice in London ruled that, in the United Kingdom, transgender minors aged ≤ 15 years are highly unlikely to fully understand the long-term effect of puberty suppression (PS) (gonadotropin-releasing hormone agonist) and to give informed consent (IC).¹ Other countries and states have considered or applied similar age-based restrictions in access to this care as well.² However, evidence regarding transgender minors' medical decision-making competence (MDC) was lacking until now. To our knowledge, the current study is the first to present empirical outcomes of assessment of transgender minors' MDC.

Transgender people have a feeling of discrepancy between their birth-assigned sex and gender identity.³ In this article, the term "(birth-assigned) sex" is used for an anatomic or chromosomal determination, as opposed to gender, which refers to an internal sense of self as man, woman, another gender or no gender. When puberty starts, transgender minors have to deal with body changes they abhor. In the 1990s, the Dutch introduced treatment with PS, which allows transgender adolescents to further mature and accrue life experience before decisions are made regarding successive gender-affirming treatment with permanent physical changes.^{4–6}

In the Netherlands, transgender adolescents undergo a diagnostic trajectory, including a psycho-diagnostic assessment and several monthly sessions with a mental health provider over a longer period of time (usually ~ 6 months), when assessing eligibility for PS. PS at early stages of puberty improves psychological functioning and ameliorates general functioning, and physical outcome may be better.^{7–9} As far as currently known, the

effects of this treatment are fully reversible when discontinued.⁶ However, there are worries about the impact of PS on physical, cognitive, and psychosocial development and the capability of making decisions about this treatment with profound implications (eg, regarding fertility) at this young age.^{9–11} Minors' MDC for interventions is a major issue in pediatric ethics. Therefore, according to the international guidelines, one of the criteria for transgender adolescents to start PS is having sufficient mental capacity to give IC.^{6,12} Of note, gonadotropin-releasing hormone agonists are standard of care for treatment in children with precocious puberty.¹³

Minors are a protected population and, in most circumstances, not accorded the legal right to consent. Local jurisdictions determine age limits for minors' alleged MDC, which vary widely between countries.^{14,15} Research reveals that minors who have not yet reached the legally set age for MDC often have the mental capacity to understand the implications of a decision.¹⁶ In contrast, minors may differ from adults by not yet having developed stable long-term goals in life and basing their decisions on values that might change.¹⁷ Additionally, minors are not as likely as adults to consider the benefits and risks associated with a decision.¹⁸ In our study, to deal with discrepancies between local laws and international jurisdictions, we focused on adolescents' decision-making competence or capacity for giving consent regarding the decision to start treatment with PS, regardless of the legal age to give IC (alone or together with their parents). In the context of our study, legally, parents have to give consent when the child is aged < 12 years; between the ages of 12 and 15

years, parents and child both have to give consent; and at age ≥ 16 years, the child is allowed to give consent independently.

MDC describes the capacities needed for making an autonomous medical decision.¹⁹ To reach MDC, a person needs to fulfill 4 criteria: (1) understand the information relevant to one's condition and the proposed treatment; (2) appreciate the nature of one's circumstances, including one's current medical situation and the underlying values; (3) reason about benefits and potential risks of the options; and (4) be able to express a choice.²⁰ MDC is relative to a specific task and context. It is 1 of the 3 prerequisites for giving a valid IC, next to being well-informed and without coercion.^{21,22}

In pediatric daily practice, MDC is generally assessed implicitly and in an unstructured way, which may lead to inconsistencies.²³ A study in which researchers reviewed 23 existing measures reveals that the MacArthur Competence Assessment Tool for Treatment (MacCAT-T) has the most empirical support for assessing MDC.^{19,24–26} The MacCAT-T proved reliable in assessing mental competence in adult patients with dementia, schizophrenia, and other psychiatric conditions.^{27–29}

The cognitive, emotional, and social abilities of minors develop over time and so do their decision-making capacities.¹⁵ Age is often considered to be the best determinant for assessing MDC.³⁰ Some research reveals that 12 years is a common age to reach MDC.³¹ Other research reveals that minors < 12 years of age may be capable of making well-considered decisions and that minors from the age of 9 years are capable of understanding the issues involved in clinical trials.^{32,33} Contributing factors for MDC are intelligence and psychological functioning.^{30,34} People with limited

cognitive capacities may have more difficulty understanding information.³⁴ Research suggests that psychiatric conditions and psychopathology might impair MDC.^{27–29}

Little research exists regarding minors' MDC.³⁵ Specifically, there is no empirical evidence on transgender adolescents' MDC to decide on PS. In clinical practice and policy making, age standards prescribed by law may have too much influence on the clinicians' assessments.³⁵ In addition, clinicians' assessments of MDC are influenced by their personal subjective views of what is in the adolescent's best interest.³⁶ The right balance needs to be struck between respecting transgender adolescents' autonomy and protecting adolescents who are not fully capable of making these decisions themselves.²³

To fill the gaps in knowledge regarding transgender adolescents' MDC, in this cross-sectional semistructured interview study, we aimed to answer the following questions:

1. Are transgender adolescents competent to give IC for starting PS, according to the standard IC procedure and the MacCAT-T?
2. What is the intermethod agreement between MDC judgements based on the standard IC procedure and the MacCAT-T?
3. What is the interrater agreement regarding MDC judgements between raters using the standard IC procedure and the MacCAT-T?
4. To what extent are age, intelligence, psychological functioning, duration of the diagnostic trajectory, sex, and family situation associated with transgender adolescents' MDC for starting PS?

METHODS

Participants

Participants were transgender adolescents visiting the Center of Expertise on Gender Dysphoria of the Amsterdam University Medical Centers, Location VUmc in Amsterdam, the Netherlands, between January 1, 2016, and December 31, 2017, or visiting the gender-identity clinic of Leiden University Medical Center, Leiden University Medical Center Curium, in Leiden, the Netherlands, between March 1, 2017, and December 31, 2017. The researchers identified the adolescents who were about to start PS through the medical files, and the adolescents and their parents were invited by the involved clinician to participate. The study protocol was approved by the institutional review boards of the participating institutions. Written information was provided, and signed IC for participation was obtained from all participants and their parents.

All adolescents visiting the clinics were eligible for study participation; there was no selection process. Not speaking Dutch and being cisgender were exclusion criteria. In this study, no distinction was made in describing the gender identity of the participants other than being transgender. The adolescents who participated in the study were, as recommended by the Standards of Care, at least at Tanner stage 2.¹² The clinics' protocols use PS until age 17 years to prepare for more definite affirming treatment by hormones and, in some individual cases, >17 years when creating rest and time for further gender-identity exploration are indicated. Seventy-four adolescents participated, whereas 206 eligible adolescents were not reached or did not want to or could not participate (Fig 1). There were no significant differences between the participating and

nonparticipating adolescents with regard to demographics (Table 1).

Measures

Demographics

Adolescents' demographic characteristics obtained from the medical files were date of birth, sex, family situation, date of the first contact at the clinic, and date of the IC session. Family situation was categorized into (1) living with both parents and (2) other.

Medical Decision-Making Competence

The MacCAT-T is a quantitative, semistructured interview used to assess the 4 MDC criteria and takes 15 to 20 minutes.^{19,20} In this study, the Dutch version modified for children and adolescents was used.³⁵ In the current study, the disclosure of information was adapted to treatment with PS in transgender adolescents.^{15,19,35} Examples of interview-questions are "what would be possible consequences if you would choose to undergo this intervention, and what if you would not?" The tool provides a total score and subscale scores for each of the 4 MDC criteria. An overall cutoff score for MDC is not provided. The assessor weighs the subscale scores, along with contextual information (eg, substantial risks of treatment, far-reaching consequences, and whether there is support of caregivers), and judges MDC in each individual case. Recent research revealed that the 4 MDC criteria constitute a continuum or single trait in children.¹⁶

Full-Scale Intelligence

Full-scale IQ was assessed by the Dutch Wechsler Intelligence Scale for Children in adolescents aged ≤16 years and by the Dutch Wechsler Adult Intelligence Scale in adolescents aged >16 years.^{37,38}




FIGURE 1
Flowchart of Adolescent Participation.

Child Behavior Checklist

The parent-reported Child Behavior Checklist (CBCL) was used to assess behavioral and emotional difficulties.^{39,40} The total-problem *T* score was calculated as age-standardized measure of total behavioral and emotional difficulties.

Procedures

Both gender-identity clinics that participate in the study follow the Standards of Care and the Endocrine Society clinical practice guidelines.^{6,12} The diagnostic trajectory, which is spread over a longer period of time, concludes with a session for signing a printed

IC statement by adolescents and parents. This standard IC session was videotaped and used to establish the reference standard for MDC in this study (see below), similar to previous studies.^{16,35} After the IC session, the MacCAT-T interview was administered by one of the researchers, which was also videotaped, to provide the MacCAT-T-based judgements of MDC.

A panel of 12 experts (including child psychiatrists, pediatric endocrinologists, child psychologists, and master thesis medical students) was trained in judging MDC on the basis of the 4 criteria, which are currently considered the generally accepted reference standard.^{16,24,41,42}

Reference Standard

Of each IC video, 3 MDC judgements were performed: 2 by experts and 1 by the clinician involved in the diagnostic trajectory. These judgements were used for establishing the reference standard.

MacCAT-T

Each MacCAT-T video was also judged by 3 different experts, who rated the subscale scores, total score, and their MDC judgement. These assessments were used for the MacCAT-T-based judgements. The experts received the videos in random order, blinded to other judgements or adolescents' characteristics.

Statistical Analyses

All statistical analyses were performed by using SPSS, version 26 (IBM SPSS Statistics, IBM Corporation).⁴³ Both for the reference standard and MacCAT-T-based judgements, MDC was considered present when at least 2 out of 3 judgements were positive.³⁵

The proportion of adolescents assessed positive on MDC was described as a raw percentage. The

TABLE 1 Comparison of Characteristics of Participating and Nonparticipating Adolescents MacCAT-T

Variables	Participating Adolescents	Nonparticipating Adolescents	<i>P</i>
Age, y			.09
<i>N</i>	73 ^a	206	
Mean	14.71	15.18	
Range	10.63–18.34	10.10–18.36	
Total IQ			.65
<i>N</i>	70 ^b	195 ^c	
Mean	100.21	99.17	
Range	66–144	61–144	
Assigned sex, <i>n</i> (%)			.39
Birth-assigned female	58 (78.4)	151 (73.3)	
Birth-assigned male	16 (21.6)	55 (26.7)	
CBCL total-problem <i>T</i> score			.25
<i>N</i>	57 ^d	183 ^e	
Mean	60.42	58.78	
Range	42–77	34–80	
Duration of diagnostic trajectory, mo			.43
<i>N</i>	73 ^a	206	
Mean	9.55	10.29	
Range	4–26	3–59	
Family situation, <i>n</i> (%)			.16
With both parents	39 (52.7)	128 (62.1)	
Other	35 (47.3)	78 (37.9)	

Age refers to age at the IC session; total IQ refers to full-scale IQ; CBCL refers to Child Behavior Checklist.

^a Date of starting with puberty-suppressing treatment was unknown for one participating adolescent.

^b Total IQ was missing for four participating adolescents.

^c Total IQ was missing for 11 nonparticipating adolescents.

^d CBCL total-problem *T* score was missing for 17 participating adolescents.

^e CBCL total-problem *T* score was missing for 23 nonparticipating adolescents.

correlation between the reference standard and MacCAT-T-based judgements, as a measure of intermethod agreement, was also described as a raw percentage. Interrater agreement of the 3 reference standard and 3 MacCAT-T-based judgements, which is the overall percentage of mean fractions of agreement between the 3 raters, were calculated as raw percentages.

To discern potential associations between MacCAT-T total-scale scores and our main variables of interest (age, intelligence, CBCL total-problem *T* score, and duration of the diagnostic trajectory), demographic characteristics were identified as relevant control variables (eg, gender, family situation, and clinic location) as a first step. Second, multiple linear regression was used to identify variables correlated to the MacCAT-T total scores with pairwise deletion of missing variables.

RESULTS

Baseline Characteristics

Participants' baseline characteristics are listed in Table 2.

MDC

After the reference standard and MacCAT-T-based judgements, respectively, 93.2% (69 of 74) and 89.2% (66 of 74) of the adolescents were positive on MDC for starting PS. Table 3 shows characteristics of participants who were judged not competent.

Intermethod Agreement

The reference standard and MacCAT-T-based judgements correlated in 87.8% (65 of 74) of the cases (see Table 4).

Interrater Agreement

The interrater agreement of the reference standard and MacCAT-T-based judgements for the 3

experts were 89.2% (198 of 222) and 86.5% (192 of 222), respectively.

Variables Related to MacCAT-T Scores

Sex was significantly associated with MacCAT-T score ($t[72] = -3.045$; $P = .003$); birth-assigned girls showed a higher total score. Both family status and clinic location were not significantly associated with MacCAT-T score. Therefore, a multiple linear regression analysis was conducted with only sex as control variable and age, intelligence, psychological functioning, and duration of the diagnostic trajectory as the main variables of interest, with the MacCAT-T score as the dependent variable. Table 5 shows the results of the multiple linear regression analysis. A significant regression equation was found ($F(5,52) = 3.685$; $P = .006$). Sex and full-scale intelligence are both significantly related to the MacCAT-T score when each one was corrected for the other 3 variables (respectively, $\beta = 3.636$; $t(52) = 2.685$; $P = .010$; and $\beta = 0.088$; $t(52) = 2.381$; $P = .02$). Age at the IC session, CBCL total-problem *T* score and duration of the diagnostic trajectory were not significantly correlated.

DISCUSSION

The current study revealed that 93.2% and 89.2% of the transgender adolescents who were about to start PS and were participating in this study were competent to give IC on the basis of the standard clinical assessment and when using the MacCAT-T interview, respectively. This is a reassuring finding, which reveals that guidelines that require understanding the pros and cons of the treatment and capacity for IC for starting PS are followed for these participants.^{6,12} This study was performed after several sessions with adolescents and parents aimed

at obtaining understanding of the consequences of PS, including not only the short-term, with regard to suppression of further feminization or virilization, but also long-term considerations of bone development, surgical options, and fertility.⁴⁴

This study further looked into several variables potentially associated with MDC. Of the examined variables, higher intelligence and sex (birth-assigned girls) were associated with higher MacCAT-T scores. The association of a higher intelligence with MDC is in line with other research.^{45,46} The birth-assigned girls in our study might have had a more advanced puberty compared with the birth-assigned boys, which might be related to a deeper understanding of the consequences of PS.⁴⁷ Contrary to our expectations and earlier research, age was not correlated to MacCAT-T scores in this study. Although the participants seem like a representative sample, it may be too homogeneous, with regard to age, to detect a significant effect because the sample included few participants aged ≤ 11 years. Most research suggests that MDC is reached little before the age of 12 years.^{16,32,33} Finally, no association between duration of the diagnostic trajectory or behavioral and emotional difficulties was found. This finding was also against our expectation because psychological difficulties can interfere with MDC. However, one of the criteria for starting PS applied at the Dutch gender-identity clinics is "having no interfering psychosocial difficulties."^{6,12} Therefore, by protocol, adolescents with severe psychosocial difficulties might have been referred for appropriate treatment before deciding on PS.

The results of this study confirm the feasibility of the Dutch version of the MacCAT-T for children and adolescents in assessing transgender adolescents'

TABLE 2 Descriptive Statistics for Characteristics of the Participants

Variables	Birth-Assigned Boys	Birth-Assigned Girls	Total	<i>P</i>
Age, y				.15
<i>n</i>	16	58	74	
Mean	14.02	14.87	14.69	
Range	12.02–17.11	10.63–18.34	10.63–18.34	
Total IQ				.82
<i>n</i>	15	55	70 ^a	
Mean	99.47	100.42	100.21	
Range	82–131	66–144	66–144	
CBCL total-problem <i>T</i> score				.91
<i>n</i>	13	48	61 ^b	
Mean	60.62	60.94	60.87	
Range	44–72	42–77	42–77	
Percentage in clinical range, % ^c	38.5	43.7	42.6	.73
Duration of diagnostic trajectory, mo				.64
<i>n</i>	16	58	74	
Mean	9.25	8.69	8.81	
Range	4–18	2–26	2–26	
Family situation, <i>n</i> (%)				.71
With both parents	8 (50.0)	32 (55.2)	40 (54.1)	
Other	8 (50.0)	26 (44.8)	34 (45.9)	

Age refers to age at the IC session; total IQ refers to full-scale IQ; CBCL refers to Child Behavior Checklist.

^a Total IQ was missing for four participants.

^b CBCL total-problem *T* score was missing for 13 participants.

^c Clinical range: $t \geq 64$ (Achenbach, 2001').

MDC; the interrater agreement of the reference standard and MacCAT-T-based judgements were both high (respectively, 89.2% and 86.5%). Furthermore, the results of this study offer first indications of validity of the MacCAT-T for judging transgender adolescents' MDC (intermethod agreement was 87.8%), and the MacCAT-T could therefore be used in clinical practice when MDC assessment is difficult. The MacCAT-T should not necessarily replace (a part of) the

usual implicit assessment of MDC. However, in individual cases of doubt on MDC, the MacCAT-T could be used as a structured tool to underpin MDC assessment more objectively. Therefore, the tool will not be a barrier for access to care but can be used for due diligence. In the MacCAT-T, contextual information is weighted in the assessment, which may include parental support. It is expected that these results will be generalizable to other clinics because findings are in line with other

research on the use of the MacCAT-T in youth (eg, in a population deciding on predictive genetic testing, in youth with HIV infection, and in a sample of adolescents with psychiatric conditions).^{35,48,49} Findings regarding the age for established MDC are congruent.

Although the study results reveal that most adolescents are considered competent to give IC for starting PS, nevertheless 6.8% to 10.8% are not, respectively, reference standard-based and MacCAT-T based. In all of these 11 adolescents assessed incompetent, except for one, the involved clinician had no doubts about the MDC.

Possibly, the more positive judgement by these clinicians may be explained by their judgement on the basis of several sessions and not on a single assessment. In the one adolescent that was assessed incompetent by the involved clinician, the clinician added that she considered the adolescent's mother competent to give (proxy) consent. So, in cases in which there is doubt regarding adolescents' MDC, clinicians may more heavily depend on the parents' IC.⁵⁰ Subsequently, time on PS could more explicitly be used to prepare MDC for treatment with lasting effects of gender-affirming hormones.

This is in line with statements in a recent qualitative study that the best interest for an individual should be taken into account when deciding whether to start PS.⁵¹ Other research reveals also that MDC assessment is regularly influenced by the clinicians' ideas of what is in the child's best interest.³⁶ This might mean that some clinicians start PS in transgender adolescents who are assessed incompetent to consent on the basis of the principle of best interest.

TABLE 3 Characteristics of Participants Judged Not Competent by Using the Reference Standard and/or MacCAT-T

Participant	Assigned Sex	Reference Standard	MacCAT-T	Age, y	Total IQ	Duration of Diagnostic Trajectory, mo
1	Female	Incompetent	Incompetent	12	69	7
2	Male	Incompetent	Incompetent	12	84	10
3	Female	Competent	Incompetent	11	93	15
4	Male	Competent	Incompetent	13	Missing	5
5	Male	Competent	Incompetent	12	96	12
6	Female	Competent	Incompetent	12	79	8
7	Female	Competent	Incompetent	17	66	10
8	Female	Competent	Incompetent	11	79	10
9	Female	Incompetent	Competent	11	Missing	7
10	Male	Incompetent	Competent	12	101	8
11	Female	Incompetent	Competent	10	110	13

Age refers to age at the IC session; total IQ refers to full-scale IQ.

TABLE 4 Percentage of Competent and Incompetent According to the Reference Standard–Based Judgements and the MacCAT-T–Based Judgements of Transgender Adolescents’ MDC

Reference Standard (<i>n</i> = 74)	MacCAT-T (<i>n</i> = 74)		Total
	Competent	Incompetent	
Competent	85.1% (63)	8.1% (6)	69
Incompetent	4.1% (3)	2.7% (2)	5
Total	66	8	74

In addition, the results of the current study do not answer questions on how to respect the developing autonomy of incompetent adolescents ethically. In the aforementioned qualitative interview study, some clinicians stated that transgender minors should at least partially depend on their parents to make decisions regarding PS.⁵¹ It could be that the parents’ role and responsibility should be more pronounced when an adolescent is deemed incompetent to consent.⁵⁰

Of note, the focus of this study was not on the putative association between MDC and having no regrets later in life about the decision to start PS. Competent transgender adolescents who begin PS may still potentially have regrets about the decision.

There are strengths and limitations to the current study. The study’s

standardized nature provided a reproducible and interrater-reliable method for assessing MDC in transgender adolescents who were about to start PS. Nevertheless, because of the study’s design to only include adolescents who were about to start PS after a diagnostic trajectory, the sample contained relatively few adolescents aged <12 years, with low intelligence, showing serious (interfering) psychiatric conditions or psychopathology, and relatively few birth-assigned boys.

Additionally, adolescent’s Tanner stage was not investigated in this study as a potential associated variable on MDC. Furthermore, on the basis of the current results, one cannot conclude with certainty whether the exploration and explanation during the diagnostic trajectory is essential in helping the transgender adolescents becoming competent to consent to PS or that MDC was already reached before the diagnostic trajectory.

TABLE 5 Multiple Linear Regression Analysis Comparing the Effect of Age, Full-Scale Intelligence, Psychological Functioning, Duration of the Diagnostic Trajectory Associated, and Sex to the MacCAT-T Score

			95% Confidence Interval for B	
	B	P	Lower Bound	Upper Bound
Step 1				
Constant	29.177	—	24.211	34.142
Assigned sex	3.636	.01*	0.923	6.348
Step 2				
Constant	18.560	—	4.977	32.143
Age	0.476	.08	−0.056	1.008
Total IQ	0.088	.02*	0.014	0.161
CBCL total-problem T score	−0.080	.19	−0.201	0.040
Duration of diagnostic trajectory	0.056	.67	−0.210	0.322

Age refers to age at the IC session; total IQ refers to full-scale IQ; CBCL refers to Child Behavior Checklist; —, not applicable.

* *P* value <.05.

In future work, researchers should especially focus on transgender adolescents aged <12 years starting this treatment, particularly birth-assigned girls who may benefit from PS as early as 9 years of age. Additional research is needed for adolescents with lower intelligence, serious developmental conditions, or psychopathology, for birth-assigned boys, and participants in early stages of puberty. More research is needed regarding the question what to do when an adolescent is incompetent to consent to the treatment; for example, what are the parents’ and the involved clinician’s role and responsibility in such a situation? In addition, qualitative research focused on the role of MDC in clinical practice and the principle of best interest are encouraged.

CONCLUSION

It is reassuring that the majority of the transgender adolescents participating in this study seem to have thoroughly thought about PS, understand what PS involves, and are deemed competent to decide. However, this might not be similar for all other contexts, particularly because our study cohort had extensive and thorough diagnostic evaluation before the MDC assessment as opposed to adolescents without this support. Additionally, the study results indicate feasibility and validity of the MacCAT-T in clinical practice. Nevertheless, as long as there are only limited data on transgender adolescents’ MDC for starting PS, an individualized approach is highly important for this group.

ACKNOWLEDGMENTS

We thank the adolescents who have participated in this study. Furthermore, we would like to thank Dr Daniel Klink, Dr Corine van Diest, Dr Floor Haven, Dr Rodney van der Linde, Dr Wieteke Elzinga, Dr Jasmijn Oliemans, Dr Stijn Pasveer,

Frederique Lichtenbeld, and the other experts of the panel who administered the MacCAT-T and standard IC sessions. We thank the clinicians who were willing to collaborate in recording the standard IC session. Additionally, we would like to thank the Alliantie Fonds of Amsterdam Public Health for funding the research project.

ABBREVIATIONS

CBCL: Child Behavior Checklist
 IC: informed consent
 MacCAT-T: MacArthur
 Competence
 Assessment Tool for
 Treatment
 MDC: medical decision-making
 competence
 PS: puberty suppression

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Address correspondent to Lieke J.J.J. Vrouwenraets, MSc, Leiden University Medical Center, Department of Medical Ethics and Health Law, Albinusdreef 2, 2333 ZA Leiden, Netherlands. E-mail: l.j.j.vrouenraets@lumc.nl

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2021 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: Funded by Alliantie Fonds of Amsterdam Public Health. The funding source had no role in the study design, in the writing of the manuscript, and in the decision to submit the manuscript for publication.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2021-053451.

REFERENCES

- Dyer C. Puberty blockers: children under 16 should not be referred without court order, says NHS England. *BMJ*. 2020;371:m4717
- Walch A, Davidge-Pitts C, Safer JD, Lopez X, Tangpricha V, Iwamoto SJ. Proper care of transgender and gender diverse persons in the setting of proposed discrimination: a policy perspective. *J Clin Endocrinol Metab*. 2021;106(2):305–308
- World Health Organization. ICD-11 for mortality and morbidity statistics: gender incongruence. Available at: <https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2fid%2fentity%2f411470068>. Accessed October 9, 2021
- Cohen-Kettenis PT, Steensma TD, de Vries ALC. Treatment of adolescents with gender dysphoria in the Netherlands. *Child Adolesc Psychiatr Clin N Am*. 2011;20(4):689–700
- Delemarre-van de Waal HA, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. *Eur J Endocrinol*. 2006;155(suppl_1):131–137
- Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2017;102(11):3869–3903
- de Vries ALC, Steensma TD, Doreleijers TAH, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. *J Sex Med*. 2011;8(8):2276–2283
- van der Miesen AIR, Steensma TD, de Vries ALC, Bos H, Popma A. Psychological functioning in transgender adolescents before and after gender affirmative care compared to cisgender general population peers. *J Adolesc Health*. 2020;66(6):699–704
- Anacker C, Sydnor E, Chen BK, et al. Behavioral and neurobiological effects of GnRH agonist treatment in mice: potential implications for puberty suppression in transgender individuals. *Neuropsychopharmacology*. 2021;46(5):882–890
- Chen D, Strang JF, Kolbuck VD, et al. Consensus parameter: research methodologies to evaluate neurodevelopmental effects of pubertal suppression in transgender youth. *Transgend Health*. 2020;5(4):246–257
- Kreukels BPC, Cohen-Kettenis PT. Puberty suppression in gender identity disorder: the Amsterdam experience. *Nat Rev Endocrinol*. 2011;7(8):466–472
- Coleman E, Bockting WO, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. *Int J Transgenderism*. 2012;13:165–232
- Carel JC, Eugster EA, Rogol A, et al; ESPE-LWPES GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009. Available at: www.pediatrics.org/cgi/content/full/123/4/e752
- Stultiëns L, Goffin T, Borry P, Dierickx K, Nys H. Minors and informed consent: a

- comparative approach. *Eur J Health Law*. 2007;14(1):21–46
15. Hein IM, Troost PW, Lindeboom R, de Vries MC, Zwaan CM, Lindauer RJ. Assessing children's competence to consent in research by a standardized tool: a validity study. *BMC Pediatr*. 2012;12:156–163
16. Hein IM, Troost PW, Lindeboom R, et al. Accuracy of the MacArthur competence assessment tool for clinical research (MacCAT-CR) for measuring children's competence to consent to clinical research. *JAMA Pediatr*. 2014;168(12):1147–1153
17. Cohen P, Cohen J. *Life Values and Adolescents Mental Health*. New York, NY: Psychology Press; 1996
18. Halpern-Felsher BL, Cauffman E. Costs and benefits of a decision: decision-making competence in adolescents and adults. *J Appl Dev Psychol*. 2001;22:257–273
19. Grisso T, Appelbaum PS, Hill-Fotouhi C. The MacCAT-T: a clinical tool to assess patients' capacities to make treatment decisions. *Psychiatr Serv*. 1997;48(11):1415–1419
20. Appelbaum PS, Grisso T. Assessing patients' capacities to consent to treatment. *N Engl J Med*. 1988;319(25):1635–1638
21. Grisso T, Appelbaum PS. Comparison of standards for assessing patients' capacities to make treatment decisions. *Am J Psychiatry*. 1995;152(7):1033–1037
22. Beauchamp TL, Childress JF. *Principles of Biomedical Ethics*. New York, NY: Oxford University Press; 2008
23. Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. *N Engl J Med*. 2007;357(18):1834–1840
24. Kim SY, Caine ED, Currier GW, Leibovici A, Ryan JM. Assessing the competence of persons with Alzheimer's disease in providing informed consent for participation in research. *Am J Psychiatry*. 2001;158(5):712–717
25. Dunn LB, Nowrangi MA, Palmer BW, Jeste DV, Saks ER. Assessing decisional capacity for clinical research or treatment: a review of instruments. *Am J Psychiatry*. 2006;163(8):1323–1334
26. Kim SY, Appelbaum PS, Swan J, et al. Determining when impairment constitutes incapacity for informed consent in schizophrenia research. *Br J Psychiatry*. 2007;191:38–43
27. Cairns R, Maddock G, Buchanan A, et al. Reliability of mental capacity assessments in psychiatric in-patients. *Br J Psychiatry*. 2005;187:372–378
28. Owen GS, Richardson G, David AS, Szmulker G, Hayward P, Hotopf M. Mental capacity to make decisions on treatment in people admitted to psychiatric hospitals: cross sectional study. *BMJ*. 2008;337:a448
29. Palmer BW, Dunn LB, Appelbaum PS, et al. Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or diabetes mellitus: comparison of a 3-item questionnaire with a comprehensive standardized capacity instrument. *Arch Gen Psychiatry*. 2005;62(7):726–733
30. Dorn LD, Susman EJ, Fletcher JC. Informed consent in children and adolescents: age, maturation and psychological state. *J Adolesc Health*. 1995;16(3):185–190
31. Billick SB, Burgert W III, Friberg G, Downer AV, Bruni-Solikhah SM. A clinical study of competency to consent to treatment in pediatrics. *J Am Acad Psychiatry Law*. 2001;29(3):298–302
32. Billick SB, Edwards JL, Burgert W III, Serlen JR, Bruni SM. A clinical study of competency in child psychiatric inpatients. *J Am Acad Psychiatry Law*. 1998;26(4):587–594
33. Mårtensson EK, Fägerskiöld AM. A review of children's decision-making competence in health care. *J Clin Nurs*. 2008;17(23):3131–3141
34. Grisso T, Appelbaum PS. *Assessing Competence to Consent to Treatment: A Guide for Physicians and Other Health Professionals*. New York, NY: Oxford University Press; 1998
35. Hein IM, Troost PW, Lindeboom R, et al. Feasibility of an assessment tool for children's competence to consent to predictive genetic testing: a pilot study. *J Genet Couns*. 2015;24(6):971–977
36. de Vries MC, Wit JM, Engberts DP, Kaspers GJ, van Leeuwen E. Pediatric oncologists' attitudes towards involving adolescents in decision-making concerning research participation. *Pediatr Blood Cancer*. 2010;55(1):123–128
37. Wechsler D. *Wechsler Intelligence Scale for Children - Third Edition - Dutch Adaptation (WISC-III-NL)*. Amsterdam: Pearson; 2005
38. Wechsler D. *Wechsler Adult Intelligence Scale, Third Edition, Dutch version (WAIS-III-NL)*. Lisse, Netherlands: Swets and Zeitlinger; 1997
39. Achenbach TM, Rescorla LA. *Manual for the ASEBA School-Age Forms & Profiles: An Integrated System of Multi-informant Assessment*. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families; 2001
40. Verhulst FC, van der Ende J. *ASEBA Manual. Questionnaires for the ages 6 to 18 years*. Rotterdam: ASEBA Netherlands; 2013
41. Etchells E, Darzins P, Silberfeld M, et al. Assessment of patient capacity to consent to treatment. *J Gen Intern Med*. 1999;14(1):27–34
42. Carney MT, Neugroschl J, Morrison RS, Marin D, Siu AL. The development and piloting of a capacity assessment tool. *J Clin Ethics*. 2001;12(1):17–23
43. IBM Corp. *IBM SPSS Statistics for Windows. Version 26.0*. Armonk, NY: IBM Corp; 2019
44. Di Ceglie D. Autonomy and decision-making in children and adolescents with gender dysphoria. In: Shaw M, Bailey S, eds. *Justice for Children and Families - A Developmental Perspective*. Cambridge, UK: Cambridge University Press; 2018:145–153
45. Hein IM, Troost PW, Lindeboom R, et al. Key factors in children's competence to consent to clinical research. *BMC Med Ethics*. 2015;16(1):74
46. Miller VA, Drotar D, Kodish E. Children's competence for assent and consent: a review of empirical findings. *Ethics Behav*. 2004;14(3):255–295
47. Koerselman K, Pekkarinen T. *The Timing of Puberty and Gender Differences in Educational Achievement. IZA Discussion Papers 10889*. Bonn, Germany: IZA Institute of Labor Economics; 2017
48. Chenneville T, Machacek M, Tan R, Lujan-Zilberman J, Emmanuel P, Rodriguez C. Decisional capacity among

- youth with HIV: results from the MacArthur Competence Tool for Treatment. *AIDS Patient Care STDS*. 2014;28(8):425–432
49. Mandarelli G, Sabatello U, Lapponi E, Pace G, Ferrara M, Ferracuti S. Treatment decision-making capacity in children and adolescents hospitalized for an acute mental disorder: the role of cognitive functioning and psychiatric symptoms. *J Child Adolesc Psychopharmacol*. 2017;27(5):462–465
 50. Giordano S, Garland F, Holm S. Gender dysphoria in adolescents: can adolescents or parents give valid consent to puberty blockers [published online ahead of print March 10, 2021]? *J Med Ethics*. doi:10.1136/medethics-2020-106999
 51. Vrouenraets LJJJ, Fredriks AM, Hannema SE, Cohen-Kettenis PT, de Vries MC. Early medical treatment of children and adolescents with gender dysphoria: An empirical ethical study. *J Adolesc Health*. 2015;57(4):367–373